AstraZeneca PLC (LON:AZN)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 198.87B +2.3% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.47 |
| Forward PE | 15.77 |
| Dividend | 2.39 (1.86%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 2,178,329 |
| Open | 12,848 |
| Previous Close | 12,854 |
| Day's Range | 12,724 - 12,912 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15,764.26 (+22.95%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,764p, which is an increase of 22.95% from the latest price.
News
AstraZeneca (AZN) Ventures into Cancer Vaccines Amid mRNA Innovation Wave
AstraZeneca (AZN) Ventures into Cancer Vaccines Amid mRNA Innovation Wave
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Can...
Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously...
AstraZeneca PLC Announces EU Approval of Enhertu for HER2-Positive Early Breast Cancer Following 53% Risk Reduction in Phase III Trial
AstraZeneca PLC announced that Enhertu has been approved in the European Union as a monotherapy for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual...
AstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting
(RTTNews) - On Tuesday, AstraZeneca (AZN) and Daiichi Sankyo (4568.T) said the European Commission approved Enhertu in the European Union, or EU as a standalone treatment after surgery for adults with...
AstraZeneca Names Onco360 National Speciality Pharmacy Partner For Zegfrovy
(RTTNews) - AstraZeneca (AZN) has selected Onco360 as a national speciality pharmacy partner for Zegfrovy (sunvozertinib), which is indicated for the treatment of adults with locally advanced or metas...
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
Innate Pharma (IPHA) announced that AstraZeneca (AZN) has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second…
AstraZeneca announces Enhertu approval in the European Union
Enhertu has been approved in the European Union, or EU, as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive…
AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced that it aims for $80 billion in total revenue by 2030, and sustained growth beyond the year.
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the...
AstraZeneca PLC Hosts Meet the Management Session at ESMO Transcript
AstraZeneca PLC Hosts Meet the Management Session at ESMO Transcript
AstraZeneca Transcript: Investor update
ESMO results included positive VOLGA bladder-cancer survival data, promising biomarker-selected EGFR combinations, DeLLphi-305 survival gains and positive OS results for Sone-Ve in gastric cancer. Management highlighted ADC growth opportunities and a substantial 2027 readout slate.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up
(RTTNews) - AstraZeneca (AZN) reported positive Phase 3 results showing that sonesitatug vedotin (Sone-Ve) significantly improved overall survival in patients with CLDN18.2-positive advanced gastric, ...
AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up
(RTTNews) - AstraZeneca (AZN) and HUTCHMED reported Phase 3 results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free and overall surviva...
Amgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer
(RTTNews) - Amgen (AMGN) and AstraZeneca (AZN) reported Phase 3 results showing that IMDELLTRA combined with IMFINZI significantly improved survival in patients with extensive-stage small cell lung ca...
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology marke...
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca’s (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for…
AstraZeneca announces results from CLARITY-Gastric01 Phase III trial
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s (AZN) sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement ...
AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso
AstraZeneca (AZN) announces positive results from the SAFFRON Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both pr...
AstraZeneca announces results from DeLLphi-305 trial of IMFINZI
Results from the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint o...
AstraZeneca announces results from VOLGA Phase III trial of IMFINZI
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with neoadjuvant enfortumab vedotin, EV, demonstrated statistically signi...
AstraZeneca's AZN Reports Breakthrough in Stomach Cancer Treatment, Boosting Dividend Appeal
AstraZeneca's AZN Reports Breakthrough in Stomach Cancer Treatment, Boosting Dividend Appeal
AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study
AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage t...
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful ...